Ceptaris, a privately held, specialty
pharmaceutical company, is developing a proprietary
formulation of mechlorethamine gel for the treatment of
early stage (stages I-IIA) mycosis fungoides, a type of
Cutaneous T-Cell Lymphoma.
Based upon results of a recently completed trial, Ceptaris
intends to file a new drug application (NDA) with the
Food and Drug Administration (FDA) in 2011. If approved,
Ceptaris' investigational drug would be the first topical
mechlorethamine product available to treat the
signs and symptoms of this rare cancer.
Ceptaris has augmented its management team with the
addition of a number of experienced pharmaceutical
executives as it approaches regulatory filing and
potential commercialization of mechlorethamine gel.